Bayer (FRA:BAYN) has been given a €105.00 ($117.98) price target by stock analysts at Baader Bank in a research report issued on Monday, Borsen Zeitung reports. The brokerage currently has a “buy” rating on the healthcare company’s stock. Baader Bank’s price target indicates a potential upside of 59.60% from the company’s current price.
Several other research firms have also weighed in on BAYN. HSBC set a €85.00 ($95.51) target price on Bayer and gave the company a “buy” rating in a report on Thursday, June 25th. Nord/LB set a €78.00 ($87.64) price objective on Bayer and gave the company a “neutral” rating in a research note on Thursday, June 25th. Barclays set a €80.00 ($89.89) price objective on Bayer and gave the company a “buy” rating in a research note on Thursday, April 9th. JPMorgan Chase & Co. set a €77.00 ($86.52) price objective on Bayer and gave the company a “neutral” rating in a research note on Thursday, June 25th. Finally, Sanford C. Bernstein set a €88.00 ($98.88) price objective on Bayer and gave the company a “buy” rating in a research note on Wednesday, June 24th. Five equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of €84.76 ($95.24).
Bayer stock opened at €65.79 ($73.92) on Monday. Bayer has a fifty-two week low of €91.58 ($102.90) and a fifty-two week high of €123.82 ($139.12). The stock’s fifty day moving average is €63.29 and its two-hundred day moving average is €65.34.
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Recommended Story: Reverse Stock Split
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.